Shareholders quiz Merck head; Genzyme sues Watson over generic Renvela plans;

 @FiercePharma: Are emerging markets enough to boost Big Pharma? Report | Follow @FiercePharma

> Shareholders of drugmaker Merck spent their annual meeting Tuesday peppering its chief executive with questions about what the company will do to boost its lagging stock price, raise dividends and improve performance. Report

> Watson Pharmaceuticals is being sued by Genzyme over its plans to make a generic version of Renvela. Report

> The U.K. agency that advises the state-run National Health Service on cost-effective treatments recommended wider use of therapies for hepatitis C. Report

> Sanofi-Aventis put its global media buying and planning account up for review, Medical Marketing & Media reports. Report

> Watson Pharmaceuticals spent $390,000 lobbying the federal government during the first quarter on issues including drug importation and safety, and healthcare reform, according to a recent disclosure. Report

> Sinopharm Group, China's biggest drug distributor, plans to buy rivals in smaller cities to tap increasing demand for healthcare in regional areas, Credit Suisse said. Report

> McKesson Corp., a pharmaceutical distribution company, will locate a $115 million distribution operation in Olive Branch, Miss. Report

Biotech News

  @FierceBiotech: Teva tackles a Rituxan biosimilar. Report | Follow @FierceBiotech

  @JohnCFierce: So much for Pfizer's two-track approach to R&D, which always looked a tad uncomfortable to me. Now one R&D lord will rule them all. | Follow @JohnCFierce

> Vertex delivers blockbuster payload of PhIII telaprevir data. Story

> GTx shares dive after toremifene flunks PhIII cancer trial. Item

> Albany Molecular looks to Asia as it chops U.S. staff. News

> FDA wants preclinical data on XenoPort's Horizant. Report

> A.P. Pharma's CEO resigns. Story

Medical Device News

> Diagnostics firm T2 Biosystems rounds up $15M in Series C. Report

> Live from MDMA: Shuren shows off transparency. Article

> RTI gets $5M in patent dispute. News

> Boston Sci resumes sales of remaining defibrillators. Story

> Virtual Radiologic purchased for $294M. Report

Drug Development News

> Oncolytics to present reovirus research results. Story

> Nanoliposomes engineered to deliver chemotherapy. News

> JCVI creats firstt self-replicating, synthetic bacterial cell. Item

> AMT reports promising cholesterol-lowering gene therapy data. Report

And Finally... New research suggests that playing in the dirt could make you happier, smarter. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.